Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Neelam A. Vashi has a total of 180 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Cutaneous Manifestations of Aging CME Part 1: The Biology of Aging and Preventative Measures

    by Michelle Lazar, Aurore D. Zhang, Eric Beltrami, Rebecca C. Clawson, Aref Moshayedi, Andrei Sharov, Vladmir Botchkarev, Mayra B.C. Maymone, Neelam A. Vashi

  • Open Access

    The Impact of Post-inflammatory Pigment Alteration After Psoriasis: Novel Data from the VISIBLE Study

    by Andrew Alexis, Amy McMichael, Neelam Vashi, Tina Bhutani, Jensen Yeung, Theodore Alkousakis, Katelyn Rowland, Olivia Choi, Tony Ma, Daphne Chan, et al.

    Introduction Post-inflammatory pigment alteration (PIPA) in skin previously affected by psoriasis is an important, often neglected problem. PIPA has a disproportionate negative impact in people with skin of color. The phase 3b VISIBLE study evaluated guselkumab efficacy and safety in participants with skin of color and moderate-to-severe plaque psoriasis (cohort A) or moderate-to-severe scalp psoriasis (cohort B). Here we report results from exploratory assessments of the quality-of-life impact of pigmentation changes as psoriasis lesions resolve and long-term skin clearance is achieved and of correlations between dyspigmentation and clinical and patient-reported outcomes. Methods Randomized (3:1) participants received guselkumab 100 mg or placebo with crossover to guselkumab at week 16. Patient-reported impact of dyspigmentation on quality of life was assessed via Skin Discoloration Impact Evaluation Questionnaire (SDIEQ). Correlations between SDIEQ, Psoriasis Area and Severity Index (PASI), and Dermatology Life Quality Index (DLQI) were assessed. Pigmentation journeys were tracked using standard and cross-polarized photographs evaluated for erythema, pigmentation, and skin tone evenness. Results Across treatment and Fitzpatrick skin type groups (N = 205), mean SDIEQ scores decreased from 8.4–9.5 (moderate impact) at baseline to 1.3–1.9 (mild impact) at week 48. Photographic improvements in pigmentation were also observed. The majority of guselkumab-treated participants achieved clear or almost clear skin at week 48. In cohort A, mean percent PASI improvement from baseline was 94.9%; in cohort B mean percent Psoriasis Scalp Severity Index improvement was 94.6%. At week 48, correlation between SDIEQ and DLQI (r = 0.7456; p < 0.001) was stronger than between PASI and DLQI (r = 0.3345; p < 0.001). Conclusion Following treatment with guselkumab, most participants achieved clear or almost clear skin and substantial improvements in skin discoloration. Exploratory analyses showed SDIEQ improvements impacted quality of life more than PASI improvements, suggesting greater attention to PIPA is warranted in comprehensive psoriasis management, especially for patients with skin of color. ClinicalTrials.gov Identifier NCT05272150.

  • Open Access

    Cosmetic Dermatology in the Digital Age

    by Aurore D. Zhang, Roxana Shirazi, Neelam A. Vashi

    Like many other industries, healthcare is constantly evolving


  • Open Access

    Alopecia areata-like hair loss after a tick bite

    by Shilpa Ghatnekar, Geetika Seth, Maya Farah, Neelam Vashi


  • Nivolumab-induced SJS/TEN-like reaction

    by Sherwin Fazelpour, Frederick Gibson, Marian Caligayahan, Neelam Vashi


  • The Concept of Beauty and Its Evolutionary Basis

    by Henriette De La Garza, Neelam A. Vashi

  • Open Access

    Topical Treatments in Atopic Dermatitis: An Expansive Review

    by Michelle Lazar, Aurore D. Zhang, Neelam A. Vashi

    Atopic dermatitis (AD) is a common inflammatory skin condition found worldwide. It impacts patient quality of life (QoL) and is thought to arise as an inflammatory response to epidermal barrier dysfunction and hypersensitivity. AD can lead to large out-of-pocket costs and increased healthcare expenses over a lifetime. An analysis of all randomized control trials conducted since 1990 on topical therapies for AD were reviewed, including 207 trials in the final analysis. It was found that an average of 226 patients were enrolled over 2.43 arms. Common topical treatments included corticosteroids, calcineurin inhibitors, JAK inhibitors, and phosphodiesterase inhibitors. The most utilized tools to identify treatment efficacy were the EASI, IGA, SCORAD, and PGA. There was a paucity of data on trials that evaluated efficacy, QoL, and cost of treatment simultaneously. This review highlights the need for comprehensive trials that evaluate multiple aspects of treatment, including financial cost and QoL impact, to ensure each patient has the best treatment modality for the management of their AD.


  • PIDASI and PIHASI: Scoring tools for assessment of postinflammatory hyperpigmentation

    by Michelle Lazar, Shawn Shih, Susruthi Rajanala, Henriette De La Garza, Kevin F. Kennedy, Neelam A. Vashi


    • 1 March 2024
      • Vol. 17  (3) , 42-47

    Effects of the COVID-19 Pandemic On Patient Social Media Use and Acceptance of Cosmetic Procedures

    by Iman F. Khan, Henriette De La Garza, Michelle Lazar, Kevin F. Kennedy, Neelam A. Vashi

    We sought to explore facets of social media usage and the effect of the COVID-19 pandemic on the acceptance of cosmetic procedures. At an outpatient dermatology clinic from October 2019 to June 2022, 175 subjects who were English and Spanish speaking and aged 18 years or older were recruited. Participants completed a questionnaire including demographic information, social media usage, perceptions of cosmetic procedures, and desire to have a cosmetic procedure. Results were grouped into a pre-COVID-19 pandemic group and post-COVID-19 pandemic group due to a natural experiment that arose. Data were analyzed to ascertain the effect of social media usage and other factors that impact desire to undergo a cosmetic procedure between patients before and after the COVID-19 pandemic. Factors resulting in differences in desire to have a cosmetic procedure included using photo editing applications (p=0.002), following celebrities and influencers on social media (p<0.001), and following social media accounts showing cosmetic results (p=0.013). There was a statistically significant change in number of participants that: followed social media accounts showing results of cosmetic procedures (pre-COVID: 31.9%, post-COVID: 50.6%, p=0.036); had thought about having a cosmetic procedure done (pre-COVID: 63.8%, post-COVID: 86.4%, p<0.001); had discussed cosmetic procedures with a physician, dermatologist, or other professional (pre-COVID: 43.6%, post-COVID: 67.9%, p=0.001); and believed that a cosmetic procedure would help their self-esteem (pre-COVID: 47.9%, post-COVID: 77.8%, p<0.001). Limitations of this study include response bias, recall bias, and single institution study design, limiting generalizability. Our findings suggest that time spent on social media and use of photo-editing applications significantly contributes to desire to undergo a cosmetic procedure and contributed to the rise of cosmetic consultations during the COVID-19 pandemic.